This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different RAS mutations and those without an identified RAS mutation.

The findings, presented at the European Society for Medical Oncology (ESMO) Congress by Dr. Zev Wainberg, professor of medicine and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, build on earlier results from the RASolute 302 trial, which showed that patients with previously treated metastatic pancreatic cancer who received daraxonrasib lived a median of 13.2 months, compared with 6.7 months for those receiving standard chemotherapy.

The latest analysis provides additional evidence that the treatment consistently provided a benefit across a broad range of patients with advanced pancreatic cancer, regardless of their tumor's RAS mutation status or previous treatment history.

Pancreatic cancer remains one of the most difficult cancers to treat, particularly when the disease has spread to other parts of the body and progressed after initial treatment.

More than 90% of pancreatic cancers have mutations in RAS genes , which help control cell growth. When mutated, these genes can continuously send signals that drive cancer growth. In this study, researchers collected detailed molecular information on all RAS mutation subsets, providing one of the largest detailed molecular analyses in metastatic pancreatic cancer.

Source link